Navigation Links
Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Date:11/6/2009

be identified in ABSSSI but the two most common Gram-positive pathogens are Staphylococcus aureus and Streptococcus pyogenes. The significant increase in the incidence of MRSA in community as well as hospital acquired infections has resulted in a need for empirical therapy of ABSSSI that is effective against MRSA.

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated $17bn in 2008.(1)

In addition to NXL103, Novexel is currently conducting two Phase II studies with NXL104 in combination with the cephalosporin antibiotic ceftazidime (CAZ/104) for serious Gram-negative infections. Patient recruitment in those studies (a) with complicated intra-abdominal infections (cIAIs) and (b) with complicated urinary tract infections (cUTIs) is nearing completion with the results expected in the first half of 2010.

A recent technical report from the European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMEA) entitled "The bacterial challenge: time to react,"(2) voiced the need to narrow the gap between multi-resistant bacteria in the EU and the development of new antibacterial agents. In particular the report highlighted the growing problem of infections caused by multi-resistant Gram negative bacteria including Pseudomonas aeruginosa. These are the types of infections that Novexel is targeting with CAZ/104.

Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in
'/>"/>

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
2. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
3. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
4. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
5. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
6. AMT Starts Development LPLChip(TM) With Progenika
7. American Association for Homecare Proposes Strong Anti-Fraud Measures in Medicare, Applauds HHS Testimony Today That Pledges to "Stop Fraud Before it Starts"
8. R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
9. BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
10. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
11. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 XRpro ... for drug discovery and development services which features ... the pharmaceutical industry, announced financial results for the ... Timothy C.  Tyson, Chairman of XRpro Sciences commented, ... successfully transition from development stage to commercial stage ...
(Date:3/27/2015)... 27, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... its previously announced registered offering of common shares in ... Pursuant to the Offering, the Company issued 7,286,432 common ... aggregate gross proceeds of approximately $1.45 billion. On March ... and Exchange Commission a final prospectus supplement to its ...
(Date:3/27/2015)... , March 27, 2015 The International Myeloma ... myeloma patients while working toward prevention and a cure ... for introducing a federal resolution (H. Res. 174) that ... as "National Multiple Myeloma Awareness Month." Currently ... worldwide, and more than 110,000 new cases are diagnosed ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
(Date:3/29/2015)... York, NY (PRWEB) March 29, 2015 ... that conduct clinical trials and research, manage data ... to help their clients reach regulation standards. Contract ... pharmaceutical and medical device manufacturing sectors. Industry operators ... from early- to late-stage clinical research for Food ...
(Date:3/29/2015)... PORTLAND, Ore. (PRWEB) March 29, 2015 ... and Marion counties in Oregon to assess the feasibility ... youth with emotional and behavioral problems and their families. ... competition to select participants that will be provided technical ... The Oregon counties join six other national awardees chosen ...
(Date:3/29/2015)... IL (PRWEB) March 29, 2015 “Health ... Brickner, “and as we learn more about the cannabinoid ... In March Homeostasis: Publius’ Go Endo-Cannabinoid Update ... health, or endo-healing, is celebrated. Publius, of The Cannabis ... 2015 National Institutes of Health (PubMed) cannabinoid system (CS) ...
(Date:3/28/2015)... Tucson, AZ. (PRWEB) March 28, 2015 ... according to a new study by researchers ... (HSPH). , Produced with the support of the Coffee ... the journal Molecular Psychiatry this past fall, the study—one ... a meta-analysis of genomic data from more than 120,000 ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians and ... and musculoskeletal diseases gathered here for the World ... time in the 17-year history of the field’s ... is an emerging non-pharmaceutical protocol for enhancing bone ... Wolff’s law, osteogenic loading at multiples of body ...
Breaking Medicine News(10 mins):Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ New on the Bryan William Brickner Blog 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2
... submitted by Age Concern and London School of Hygiene and ... years are having an increased threat for disease due to ... that old age people are not spending the required amount ... eye care costs and are not undergoing the recommended 30 ...
... and doctors, and increases medical error risks, according to ... heating and cooling systems and by loud voices of ... short-term memory, according to the study by Johns Hopkins ... two-year research project, acoustics experts Ilene Busch-Vishniac and James ...
... that more lizard families than assumed till now are ... , The researchers, writing in the journal Nature ... like pain and swelling from lizard bites, which were ... of meat left between their teeth from their scavenging ...
... diabetes as a strong risk factor for sudden cardiac ... the disease.// ,The authors writing in the October ... prevalence of diabetes mellitus in industrialized countries is rapidly ... high risk for sudden cardiac death. ,The ...
... organisms, are exposed to ever-changing environments, oxidative stress, ... to defend themselves against all these insults, gain ... simply by ‘stealing’ genetic information from other better-adapted ... sex, known as horizontal gene transfer. ...
... A dengue fever vaccine full of promise is being tried ... of the GlaxoSmithKline vaccine //have been completed in the US ... be finished by the end of next year, Dr. Hans ... strong interest in making the vaccine available fast, given that ...
Cached Medicine News:Health News:More Lizards, Including Pets, Found Venomous 2Health News:Bacteria Evolve Armamentarium Against Antibiotics By ‘Stealing’ Gen 2
... Reichert MK1 Keratometer now utilizes ... consistent lighting, removing the need ... we didnt change are all ... made our Keratometer the worldwide ...
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
... The innovative E.coli ... Pro-Lab offers definitive identification ... the use of a ... the possibility of cross-reactions ...
Inquire...
Medicine Products: